Immunocore (IMCR) Stock Price, News & Analysis

Company Overview

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapies designed to treat cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and redirect the patient’s T cells to destroy those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is a bispecific TCR therapy approved in the United States and Europe for certain adults with unresectable or metastatic uveal melanoma, a rare form of eye cancer. Immunocore is also developing additional ImmTAC medicines for other solid tumors, hematologic cancers, infectious diseases and autoimmune conditions.

Founded in 2008 and headquartered in Abingdon, England, Immunocore serves international markets through its commercial and development operations in the United States and Europe, as well as through global clinical and regulatory activities. The company is led by Chief Executive Officer Bahija Jallal.

Key Stats

• Today's Range: $29.03 to $29.73
• 50-Day Range: $29.09 to $37.57
• 52-Week Range: $27.56 to $40.71
• Volume: 452,840 shs
• Average Volume: 438,706 shs
• Market Capitalization: $1.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.38
• Consensus Rating: Moderate Buy

Immunocore Stock Analysis - MarketRank™

Immunocore scored higher than 66% of companies evaluated by MarketBeat, and ranked 322nd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Immunocore has a consensus price target of $56.38, representing about 91.8% upside from its current price of $29.39.

Amount of Analyst Coverage

Immunocore has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 316.67%

Earnings Growth

Earnings for Immunocore are expected to grow by 316.67% in the coming year, from $0.06 to $0.25 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunocore is -79.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunocore is -79.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunocore has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.07% of the float of Immunocore has been sold short.

Short Interest Ratio / Days to Cover

Immunocore has a short interest ratio ("days to cover") of 20.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunocore has recently increased by 1.71%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunocore does not currently pay a dividend.

Dividend Growth

Immunocore does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Immunocore has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Immunocore this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for IMCR on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immunocore insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.10% of the stock of Immunocore is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/11/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMCR
• CIK: 1671927
• Web: www.immunocore.com
• Phone: 44-12-3543-8600
• Fax: N/A
• Employees: 524
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Immunocore: $56.38
• High Price Target: $100.00
• Low Price Target: $33.00
• Potential Upside/Downside: +91.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 489.83
• P/E Growth: N/A
• Net Income: -$35.51 million
• Net Margins: -4.20%
• Pretax Margin: -0.63%
• Return on Equity: -4.54%
• Return on Assets: -1.66%

Debt

• Debt-to-Equity Ratio: 0.94
• Current Ratio: 4.47
• Quick Ratio: 4.44

Sales & Book Value

• Annual Sales: $400.02 million
• Price / Sales: 3.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.52 per share
• Price / Book: 3.91

Miscellaneous

• Outstanding Shares: 51,500,000
• Free Float: 46,298,000
• Market Cap: $1.51 billion
• Optionable: Optionable
• Beta: 0.81